俊宏固肾生发丸品牌怎么样 申请店铺

我要投票 俊宏固肾生发丸在生发行业中的票数:725 更新时间:2025-12-14
俊宏固肾生发丸是哪个国家的品牌?「俊宏固肾生发丸」是 吉林省俊宏药业有限公司 旗下著名品牌。该品牌发源于吉林省通化市,由创始人张士俊在2001-09-04期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力俊宏固肾生发丸品牌出海!将品牌入驻外推网,定制俊宏固肾生发丸品牌推广信息,可以显著提高俊宏固肾生发丸产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

俊宏固肾生发丸怎么样

辉南县位于中药材资源丰富的长白山麓松花江畔,地处吉林省东南部,隶属通化市管辖,东南与靖宇县毗邻,西距梅河口市45公里,南与柳河县接壤,东与桦甸市相边,北与磐石市隔江相望,县城朝阳镇位于辉南县西北角部,素有“参鹿之乡,医药名城”之美誉。俊宏药业有限公司就位于县城东北部,辉南经济开发区内。

俊宏药业有限公司成立于1990年,注册资金5000万元,2001年由长春搬迁到辉南,并按GMP标准实施改造工程。于2003年初整体通过了国家药品GMP认证并投入正式生产。公司类型为民营有限责任公司,资产总额5.5亿元。公司占地面积21万平方米,建筑面积5.8万平方米,现有员210人,各类专业技术人员70余人,其中具有高级职称9人,职业药师7人。公司现有前处理提取车间、固体制剂车间、保健用品车间、中心化验室等四个车间和七个职能管理科室。有胶囊剂、片剂、颗粒剂、散剂、水丸、蜜丸、浓缩丸、水蜜丸、糊丸、中药饮片和贴膏剂、软膏剂、液体制剂等13个剂型,共有87个国药准字号中成药生产品种和33个吉卫健用字号保健用品生产品种,其中获国家中药保护品种1个。公司拥有完备的生产设备和精湛的工艺技术,是一个已通过新修订的国家药品GMP认证、以固体制剂为主体的现代化中成药制药和保健用品生产企业。

公司自成立以来一贯奉行以市场为导向,以产品为载体,以质量为生命的生产经营宗旨。按照现代化企业制度的要求,规范管理机制,强化营销策略,坚持内抓管理,外拓市场,以质量求生存,靠信誉求发展的经营理念。凭借高质量的产品和良好的商业信誉,已在全国大部分省市建立了自己的销售网络,产品销售量逐年增加,各项经济指标逐年增长。

公司把建设“规模强大,实力雄厚,效益显著”的科技创新型企业作为发展战略,已与省中医药研究院、吉大药学院等科研机构、大专院校建立了合作关系,成功开发了一系列新药特药,其中研制开发的保健用品产品种已获批号33个,目前已正式投产上市,公司将不断研制开发高科技新产品,以使企业实力不断增强,朝更高、更强的目标迈进,为医药行业的繁荣发展而做出贡献。


Huinan County is located on the Bank of Songhua River at the foot of Changbai Mountain, which is rich in traditional Chinese medicine resources. It is under the jurisdiction of Tonghua city. It is adjacent to Jingyu County in the southeast, 45km away from Meihekou city in the west, Liuhe County in the south, Huadian City in the East and Panshi City in the north. Chaoyang Town, located in the northwest corner of Huinan County, is known as the "hometown of shenlu and famous medical city". Junhong Pharmaceutical Co., Ltd. is located in Huinan Economic Development Zone in the north of the east of the county. Junhong Pharmaceutical Co., Ltd. was founded in 1990 with a registered capital of 50 million yuan. It was moved from Changchun to Huinan in 2001, and the transformation project was implemented according to GMP standards. At the beginning of 2003, it passed the national GMP certification and put into formal production. The company is a private limited liability company with total assets of RMB 550 million. The company covers an area of 210000 square meters, with a building area of 58000 square meters. There are 210 employees and more than 70 professional and technical personnel, including 9 with senior titles and 7 professional pharmacists. The company has four workshops and seven functional management departments, including pretreatment and extraction workshop, solid preparation workshop, health care supplies workshop, and central laboratory. There are 13 dosage forms including capsule, tablet, granule, powder, water pill, honey pill, concentrated pill, water honey pill, paste pill, Chinese herbal pieces and pastes, ointment, liquid preparation, etc. there are 87 production varieties of Chinese patent medicine under the state drug registration number and 33 production varieties of health care products under the Ji Wei Jian use number, of which one is under the state protection of traditional Chinese medicine. The company has complete production equipment and exquisite technology. It is a modern Chinese patent medicine and health care products manufacturer that has passed the newly revised national GMP certification and takes solid preparations as the main body. Since its establishment, the company has always adhered to the production and operation tenet of market-oriented, product-oriented and quality-oriented. According to the requirements of modern enterprise system, standardize the management mechanism, strengthen the marketing strategy, adhere to the business philosophy of internal management, external market expansion, survival by quality and development by reputation. With high-quality products and good business reputation, we have established our own sales network in most provinces and cities of the country. The sales volume of products increases year by year, and the economic indicators increase year by year. The company takes the construction of a scientific and technological innovation enterprise with "strong scale, strong strength and remarkable benefits" as its development strategy. It has established cooperative relations with scientific research institutions and colleges and universities such as Provincial Institute of traditional Chinese medicine, Jida College of medicine, etc., and has successfully developed a series of new drugs and specialty drugs, including 33 batches of health care products, which have been officially put into production and listed. The company will We will continue to develop new high-tech products, so as to enhance the strength of the enterprise, move towards a higher and stronger goal, and contribute to the prosperity and development of the pharmaceutical industry.

本文链接: https://brand.waitui.com/e70e8902c.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

2025年人工智能核心产业规模有望破万亿元

12月14日,从中国信息通信研究院了解到,今年以来,我国人工智能产业呈加速发展态势,2025年人工智能核心产业规模有望突破万亿元。数据显示,今年以来,生产制造环节的大模型应用增长显著,应用案例占比由去年的19.9%增长至25.9%,带动人工智能产业规模快速增长。(央视新闻)

43分钟前

近一周逾260家公司获机构调研 中科曙光和海光信息获调研数最多

近一周获得机构调研的个股有260多只,中科曙光和海光信息调研机构数最多。中科曙光和海光信息近一周有341家机构调研。中科曙光方面表示,尽管重组终止,但海光与曙光仍将在保持上市公司独立性基础上深化协同。安克创新、伟创电气等个股也均获得逾百家机构调研。从市场表现来看,近一周机构调研股月内平均上涨近1%。超捷股份、霍莱沃、斯瑞新材、博盈特焊、华菱线缆等个股均涨逾20%。(人民财讯)

44分钟前

调查:美联储明年1月降息25个基点的概率为24.4%

12月14日,据CME“美联储观察”:美联储2026年1月降息25个基点的概率为24.4%,维持利率不变的概率为75.69%。美联储到明年3月累计降息25个基点的概率为41.4%,维持利率不变的概率为50.5%,累计降息50个基点的概率为8.1%。(界面新闻)

44分钟前

万科三个展期议案均未获通过 仍有5个工作日宽限期

12月13日公告显示,万科“22万科MTN004”持有人会议三项展期议案均未获有效通过,核心展期规则均为展期一年且期间不付本息,差异在增信安排。议案一未设增信,无人同意;议案二增信加调整本息兑付,获83.40%同意;议案三仅一票同意。万科还有5个工作日宽限期谈判。(新浪财经)

44分钟前

2030年我国天然气产量将达3000亿立方米

《中国油气行业“十四五”发展成就报告》显示,中国正加速迈向现代油气产业发展新阶段,能源结构日趋多元均衡,2030年我国天然气产量将达到3000亿立方米。报告显示,“十四五”期间我国累计新增探明地质储量石油70亿吨、天然气7万亿立方米,分别较“十三五”增长约43%、40%,油气产量创历史新高。(央视新闻)

44分钟前

本页详细列出关于俊宏固肾生发丸的品牌信息,含品牌所属公司介绍,俊宏固肾生发丸所处行业的品牌地位及优势。
咨询